Comparison of the effect of Evening primrose oil with Misoprostol on cervical ripening before hysteroscopy in women without a previous vaginal delivery.

Comparison of the effect of Evening primrose oil with Misoprostol on cervical ripening before hysteroscopy in women without a previous vaginal delivery. A double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220930056059N2

Enrollment

100

Registered

2022-12-28

Start date

2022-12-31

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leiomyoma of uterus. Leiomyoma of uterus

Interventions

Intervention 1: Intervention group: 1 capsules of evening primrose 1000 mg (made by Dana Pharma company)is inserted in the posterior fornix 4 to 6 hours before surgery. Intervention 2: Control group:2

Eligibility

Sex/Gender

Female

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Women candidates for hysteroscopy Candidate for hysteroscopy Aged 25-75 years non-pregnant The patient consent to participate in the study Who have no history of natural childbirth or cervical manipulation

Exclusion criteria

Exclusion criteria: Those who had a contraindication to PGs (history of severe asthma, glaucoma, preexisting cardiac disease, hypertension, or renal failure, bleeding disorders or consuming medications that inhibit blood clotting Patients with a history of schizophrenia who take phenothiazines patients with epilepsy and seizure Significant uterovaginal prolapse precluding the administration of vaginal tablets

Design outcomes

Primary

Measure	Time frame
Size of first input hegar dilator. Timepoint: At the beginning of the study and immediately after the hysteroscopy (4-6 hours after taking the drug). Method of measurement: Measurement of cervical dilatation: Hegar dilator.	—

Secondary

Measure	Time frame
Complications of the drug before, during and after hysteroscopy. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Clinical observation.;Cervical consistency after drug administration. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Check the consistency of the cervix with a finger examination, Hegar Dilator.;Duration of cervical dilatation. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Timing.;The total duration of surgery. Timepoint: During the operation. Method of measurement: Timing.	—

Measure

Time frame

Complications of the drug before, during and after hysteroscopy. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Clinical observation.;Cervical consistency after drug administration. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Check the consistency of the cervix with a finger examination, Hegar Dilator.;Duration of cervical dilatation. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Timing.;The total duration of surgery. Timepoint: During the operation. Method of measurement: Timing.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Maryam Vaezi

Tabriz University of Medical Sciences

mva260@yahoo.com+98 41 3551 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026